Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ -1.67%11 Debt-to-EBITDA is 2.60 as of Dec. 2025, which is 37% below its 10-year median of 4.10. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Sandoz Group AG ranks worse than 66.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sandoz Group AG's Debt-to-EBITDA or its related term are showing as below:
XSWX:SDZ'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.2 Med: 4.1 Max: 6.54
Current: 2.86
During the past 4 years, the highest Debt-to-EBITDA Ratio of Sandoz Group AG was 6.54. The lowest was 0.20. And the median was 4.10.
XSWX:SDZ's Debt-to-EBITDA is ranked worse than 66.52% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs XSWX:SDZ: 2.86
Sandoz Group AG (XSWX:SDZ) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sandoz Group AG Debt-to-EBITDA Related Terms
Sandoz Group AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SDZ vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Sandoz Group AG (XSWX:SDZ) has a Debt-to-EBITDA of 2.60 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sandoz Group AG. This is 37% below median its historical median of 4.10. Over the past decade, Sandoz Group AG's Debt-to-EBITDA has ranged from 0.20 to 6.54. According to the industry distribution chart, Sandoz Group AG ranks #459 out of 690 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is Sandoz Group AG's Debt-to-EBITDA too high?
Sandoz Group AG's current Debt-to-EBITDA of 2.60 is 37% below median its 10-year median of 4.10. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 6.54. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Sandoz Group AG's value of 2.60 is 54.8% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #459 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #459 out of 690 companies for Debt-to-EBITDA. This places Sandoz Group AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Sandoz Group AG's value of 2.60 is 54.8% above this benchmark. Historically, Sandoz Group AG's own Debt-to-EBITDA has ranged from 0.20 to 6.54 over the past decade. While the company's 10-year median is 4.10 vs. the industry median of 1.68, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current Debt-to-EBITDA of 2.60 is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sandoz Group AG. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Debt-to-EBITDA is 2.60, which is 37% below median its own 10-year median of 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Debt-to-EBITDA of 2.60. The current Debt-to-EBITDA is 2.60, which is 37% below median its 10-year median of 4.10 and 54.8% above the Drug Manufacturers industry median of 1.68. Sandoz Group AG's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Debt-to-EBITDA is 2.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score
Get the complete analysis for XSWX:SDZ
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
